Search Results

Your search for Robert J. Motzer, MD,Robert J. Motzer, MD matches 52 pages

Showing 51 - 52

By Matthew Stenger / Monday, February 24, 2014 11:18 AM

No Progression-Free Survival Difference for Dovitinib vs Sorafenib in Third-Line Targeted Treatment of Metastatic Renal Cell Carcinoma

Fibroblast growth factor (FGF) pathway activation may be a mechanism of escape from vascular endothelial growth factor (VEGF)-targeted therapies. In a phase III trial reported in The Lancet Oncology, Motzer et al compared the VEGF and FGF receptor tyrosine kinase inhibitor dovitinib vs sorafenib...

kidney cancer

By Matthew Stenger / Friday, September 13, 2013 1:06 PM

Tivozanib Improves Progression-Free Survival but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma

Tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. In a phase III trial reported in Journal of Clinical Oncology by Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC) and colleagues, tivozanib was found to...

Jun

Today In Oncology

Search Results

Your search for Robert J. Motzer, MD,Robert J. Motzer, MD matches 52 pages

No Progression-Free Survival Difference for Dovitinib vs Sorafenib in Third-Line Targeted Treatment of Metastatic Renal Cell Carcinoma

Tivozanib Improves Progression-Free Survival but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma

Early Palliative Care Improves Quality of Life for Patients With Breast Cancer in India

Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

Advanced Breast Cancer Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC

Educational Gaps Found in Cardio-Oncology Training